Prediction of sensitivity and tolerance of anticancer drug for biliary tract cancer by applying a combination of targeted proteomics and metabolomic analyses.
Project/Area Number |
22390254
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Tohoku University |
Principal Investigator |
UNNO Michiaki 東北大学, 大学院・医学系研究科, 教授 (70282043)
|
Co-Investigator(Kenkyū-buntansha) |
KATAYOSE Yu 東北大学, 大学院・医学系研究科, 准教授 (20302151)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2012: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2011: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2010: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
Keywords | 胆道癌 / 膵癌 / 塩酸ゲムシタビン / トランスポーター / 薬剤感受性 / 薬剤耐性 |
Research Abstract |
To predict the effect of anti-cancer drugs, such as gemcitabine in pancreatic cancer and biliary tract cancer, is also crucial to improve QOL of patients not only improve the survival rate. By combination of targeted proteomics and metabolomic analysese, we investigated the quantitation of membrane transporters and enzymes for drug metabolism using the biliary tract cancer and pancreatic cancer cell line. We found that reduced expression of deoxycitidine kinase (dCK) are brought anticancer drug resistance. Now, we are analyzing the surgical specimens of biliary tract cancer and pancreatic cancer and referring to clinical outcome.
|
Report
(4 results)
Research Products
(50 results)
-
[Journal Article] Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues2013
Author(s)
Takadate T, Onogawa T, Fukuda T, Motoi F, Suzuki T, Fujii K, Kihara M, Mikami S, Bando Y, Maeda S, Ishida K, Minowa T, Hanagata N, Ohtsuka H, Yu Katayose, Egawa S, Nishimura T, Unno M.
-
Journal Title
Int. J. Cancer
Volume: 132
Pages: 1368-1382
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Lymph Nodes Metastasis is a Risk Factor for Bone Metastasis From Extrahepatic Cholangiocarcinoma2012
Author(s)
Katayose Y, Nakagawa K, Yamamoto K, Yoshida H, Hayashi H, Mizuma M, Ohtsuka H, Fukase K, Onogawa T, Motoi F, Rikiyama T, Egawa S, Unno M.
-
Journal Title
Hepatogastroenterology
Volume: 59
Pages: 1758-1760
DOI
Related Report
Peer Reviewed
-
[Journal Article] An analysis of asecond-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer2012
Author(s)
Katayose Y, Ohtsuka H, Kitamura Y, Masuda K, Nakagawa K, Yamamoto K, Yoshida H, Onogawa T, Motoi F, Naitoh T, Rikiyama T, Egawa S-I, Unno M.
-
Journal Title
Hepatogastroenterology
Volume: 59
Pages: 691-695
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Nm23/Nucleoside Diphosphate Kinase-A as a Potent Prognostic marker in Invasive Pancreatic Ductal Carcinoma Identified by Proteomic Analysis of Laser Micro-dissected Formalin-Fixed Paraffin-Embedded Tissue2012
Author(s)
Takadate T, Onogawa T, Fujii K, Motoi F, Mikami S, Fukuda T, Kihara M, Suzuki T, Takemura T, Minowa T, Hanagata N, Kinoshita K, Morikawa T, Shirasaki K, Rikiyama T, Katayose Y, Egawa S, Nishimura T, Unno M.
-
Journal Title
Clin Proteomics
Volume: 9
Pages: 8-8
DOI
Related Report
Peer Reviewed
-
[Journal Article] DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem2012
Author(s)
Saiki Y, Yoshino Y, Fujimura H, Manabe T, Kudo Y, Shimada M, Mano N, Nakano T, Lee Y, Shimizu S, Oba S, Fujiwara S, Shimizu H, Chen N, Nezhad ZK, Jin G, Fukushige S, Sunamura M, Ishida M, Motoi F, Egawa S, Unno M, Horii A.
-
Journal Title
Biophys. Res. Commun
Volume: 421
Pages: 98-104
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Phase I trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study)2011
Author(s)
Katayose Y, Rikiyama T, Motoi F, Yamamoto K, Yoshida H, Morikawa T, Hayashi H, Kanno A, Hirota M, Satoh K, Ariga H, Suzuki M, Ohyauchi M, Kondo Y, Ikeya S, Ogawa Y, Shimosegawa T, Egawa S, Unno M.
-
Journal Title
Hepatogastroenterology
Volume: 58
Pages: 1866-1872
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study2011
Author(s)
Maeda S, Motoi F, Onogawa T, Morikawa T, Shigeru O, Sakata N, Takadate T, Naitoh T, Rikiyama T, Katayose Y, Egawa S, Unno M
-
Journal Title
Int. J. Clin. Oncol
Volume: 16
Pages: 539-545
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 膵癌の外科治療成績の向上をめざして術前化学療法の有用性の検証からみた最適レジメンの探索元井冬彦(東北大学消化器外科)2012
Author(s)
青木豪,深瀬耕二,水間正道,大塚英郎,坂田直昭,森川孝則,林洋毅,中川圭,岡田恭穂,吉田寛,内藤剛,片寄友,江川新一,海野倫明
Organizer
第74回日本臨床外科学会
Place of Presentation
東京
Year and Date
2012-12-01
Related Report
-
[Presentation] 肝門部胆管癌の治療戦略当科における肝門部胆管癌の治療戦略と切除成績水間正道(東北大学病院肝胆膵外科)2012
Author(s)
吉田寛,林洋毅,中川圭,岡田恭穂,森川孝則,大塚英郎,乙供茂,坂田直昭,深瀬耕二,青木豪,元井冬彦,内藤剛,片寄友,海野倫明
Organizer
第74回日本臨床外科学会
Place of Presentation
東京
Year and Date
2012-11-30
Related Report
-
-
-
[Presentation] ゲムシタビン耐性胆道癌に対するS-1の効果と有害事象の検討片寄友(東北大学肝胆膵外科)2012
Author(s)
大塚英郎,北村洋,益田邦洋,中川圭,山本久仁治,吉田寛,森川孝則,元井冬彦,力山敏樹,林洋毅,水間正道,海野倫明
Organizer
第48回日本胆道学会
Place of Presentation
東京
Year and Date
2012-09-21
Related Report
-
-
-
[Presentation] アーカイブFFPE組織からの質量分析基盤プロテオーム解析に基づく膵癌治療抵抗性予測小野川徹(東北大学病院肝胆膵外科)2012
Author(s)
元井冬彦,高舘達之,森川孝則,前田晋平,白崎圭一,吉田寛,内藤剛,力山敏樹,片寄友,江川新一,海野倫明
Organizer
第43回日本膵臓学会
Place of Presentation
山形
Year and Date
2012-06-28
Related Report
-
-
-
-
-
[Presentation] 化学療法の進歩に伴う進行膵胆道癌の手術適応膵癌切除例における術前補助化学療法江川新一(東北大学肝胆膵外科)2012
Author(s)
元井冬彦,石田晶玄,深瀬耕二,水間正道,坂田直昭,乙供茂,大塚英郎,森川孝則,林洋毅,中川圭,岡田恭穂,小野川徹,吉田寛,内藤剛,力山敏樹,片寄友,海野倫明
Organizer
第112回日本外科学会
Place of Presentation
幕張
Year and Date
2012-04-12
Related Report
-
-
-
-
-